A randomized, open-label study of 800 mg lopinavir/200 mg ritonavir QD [once daily] in combination with tenofovir [disoproxil fumarate] and emtricitabine vs. 400 mg lopinavir/100 mg ritonavir bid [twice daily] in combination with tenofovir and emtricitabine in HIV-infected antiretroviral naive subjects

Trial Profile

A randomized, open-label study of 800 mg lopinavir/200 mg ritonavir QD [once daily] in combination with tenofovir [disoproxil fumarate] and emtricitabine vs. 400 mg lopinavir/100 mg ritonavir bid [twice daily] in combination with tenofovir and emtricitabine in HIV-infected antiretroviral naive subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2006

At a glance

  • Drugs Emtricitabine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top